Table 1.
NRF2 mutation in cancer cell lines and cancer patients
| Sample name | Nucleotide mutation | Amino acid change | Tumor histology | Gender | Smoking status | Age |
|---|---|---|---|---|---|---|
| LK-1 | 239 C–G (heterozygous) | T80K | SQ | Male | Current | 68 |
| LK-8 | 101 G–A (heterozygous) | R34Q | SQ | Male | Current | 57 |
| LK-9 | 72 G–C (heterozygous) | W24C | SQ | Female | Former | 73 |
| LK-17 | 235 G–A (heterozygous) | E79K | SQ | Male | Former | 73 |
| LK-29 | 245 A–G (heterozygous) | E82G | SQ | Male | Former | 70 |
| LK-31 | 235 G–A (heterozygous) | E79K | SQ | Male | Current | 71 |
| LK-39 | 95 T–G (heterozygous) | V32T | SQ | Male | Former | 74 |
| LK-40 | 88 C–T (homozygous) | L30F | SQ | Male | Current | 70 |
| LK-47 | 83 T–C (heterozygous) | I28T | SQ | Female | Never | 59 |
| LK-72 | 235 G–C (heterozygous) | E79Q | AD | Male | Former | 75 |
| LK-102 | 72 G–C (heterozygous) | W24C | LCNEC | Male | Current | 77 |
| HN-3 | 225 A-C (heterozygous) | Q75H | HN | Female | Former | 51 |
| HN-5 | 239 C-T (heterozygous) | T80I | HN | Male | Never | 58 |
| HN-10 | 86 A-G (heterozygous) | D29G | HN | Male | Current | 74 |
| EBC-1 | 230 A–T (heterozygous) | D77V | NSCLC | NA | NA | NA |
| LK2 | 235 G–A (homozygous) | E79K | NSCLC | NA | NA | NA |
| HO1-U1 | 246 A–T (heterozygous) | E82D | OC | NA | NA | NA |